Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls

World Journal of Biological Psychiatry

Volumn 11, Issue 5, 2010, Pages 719-728

  Martins De Souza, Daniel ^a,c   Wobrock, Thomas ^b   Zerr, Inga ^b   Schmitt, Andrea ^b,c   Gawinecka, Joanna ^b   Schneider Axmann, Thomas ^b   Falkai, Peter ^b   Turck, Christoph W ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Apolipoprotein E A1; CSF; Prostaglandin H2 D isomerase; Proteomics; Schizophrenia

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN E; ISOMERASE; PREALBUMIN; PROSTAGLANDIN H2; SYNAPSIN II; TRANSFORMING GROWTH FACTOR BETA1; LIPOCALIN; PHOSPHOLIPID; PROSTAGLANDIN R2 D-ISOMERASE; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CHOLESTEROL METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MASS SPECTROMETRY; PHOSPHOLIPID METABOLISM; PROTEIN EXPRESSION; SCHIZOPHRENIA; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING; DOWN REGULATION; PHYSIOLOGY; PROTEOMICS; PSYCHOLOGICAL RATING SCALE; REFERENCE VALUE; UPREGULATION; YOUNG ADULT;

ADULT; APOLIPOPROTEIN A-I; APOLIPOPROTEINS E; BLOTTING, WESTERN; DOWN-REGULATION; FEMALE; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; LIPOCALINS; MALE; PHOSPHOLIPIDS; PREALBUMIN; PROTEOMICS; PSYCHIATRIC STATUS RATING SCALES; REFERENCE VALUES; SCHIZOPHRENIA; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION; YOUNG ADULT;

EID: 77954351614     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622971003758748     Document Type: Article

References (73)

1. Arnold SE, Joo E, Martinoli MG, Roy N, Trojanowski JQ, Gur RE, et al. 1997. Apolipoprotein E genotype in schizophrenia: frequency, age of onset, and neuropathologic features. Neu-roreport 8(6):1523-1526.
2. Bassett AS, Collins EJ, Nuttall SE, Honer WG. 1993. Positive and negative symptoms in families with schizophrenia. Schizophr Res 11:9-19.
3. Bosetti F, Weerasinghe GR, Rosenberger TA, Rapoport SI. 2003. Valproic acid down-regulates the conversion of arachidonic acid to eicosanoids via cyclooxygenase-1 and-2 in rat brain. J Neurochem 85(3):690-696.
4. Boston PF, Dursun SM, Zafar R, Reveley MA. 1996. Serum cholesterol and treatment-resistance in schizophrenia. Biol Psychiatry 40(6):542-543.
5. Brum IJB, Martins-de-Souza D, Smolka MB, Novello JC, Galembeck E. 2009. Web based theoretical protein pI, MW and 2DE map. J Comput Sci Syst Biol 2:93-96.
6. Bu G. 2009 Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 10(5):333-344.
7. Chen JY, Hong CJ, Chiu HJ, Lin CY, Bai YM, Song HL, et al. 1999. Apolipoprotein E genotype and schizophrenia. Neuropsychobiology 39(3):141-143.
8. Dean B, Laws SM, Hone E, Taddei K, Scarr E, Thomas EA, et al. 2003. Increased levels of apolipoprotein E in the frontal cortex of subjects with schizophrenia. Biol Psychiatry 54(6): 616-622.
9. Dean B, Digney A, Sundram S, Thomas E, Scarr E. 2008. Plasma apolipoprotein E is decreased in schizophrenia spectrum and bipolar disorder. Psychiatry Res 158(1):75-78.
10. Digney A, Keriakous D, Scarr E, Thomas E, Dean B. 2005. Differential changes in apolipoprotein E in schizophrenia and bipolar I disorder. Biol Psychiatry 57(7):711-715. (Pubitemid 40487914)
11. Durany N, Riederer P, Cruz-Sánchez FF. 2000. Apolipoprotein E genotype in Spanish schizophrenic patients. Psychiatr Genet 10(2):73-77.
12. Endicott J, Spitzer RL, Fleiss JL, Cohen J. 1976. The Global Assessment Scale: A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 33: 766-771.
13. Fendt M, Lex A, Falkai P, Henn FA, Schmitt A. 2008. Behavioural alterations after postnatal hypoxia and effects of clozapine: implications for schizophrenia. Pharmacopsychiatry 41(4): 138-145.
14. Gattaz WF, Hübner CV, Nevalainen TJ, Thuren T, Kinnunen PK. 1990. Increased serum phospholipase A2 activity in schizophrenia: a replication study. Biol Psychiatry 28(6):495-501
15. Guy W, Bonato RR, eds. 1976. CGI: Clinical Global Impressions. In: Manual for the ECDEU Assessment Battery. 2nd rev ed. Chevy Chase, MD: National Institute of Mental Health. p. 12/1-12/6.
16. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD, et al. 2001. Genome-wide expression analysis reveals dysregu-lation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci USA 98(8):4746-4751.
17. Harrington CR, Roth M, Xuereb JH, McKenna PJ, Wischik CM. 1995. Apolipoprotein E type epsilon 4 allele frequency is increased in patients with schizophrenia. Neurosci Lett 202 (1-2):101-104.
18. Hong CJ, Yu YW, Lin CH, Song HL, Lai HC, Yang KH, Tsai SJ. 2000. Association study of apolipoprotein E epsilon4 with clinical phenotype and clozapine response in schizophrenia. Neuropsychobiology 42(4):172-174.
19. Horrobin DF, Glen AI, Vaddadi K. 1994. The membrane hypothesis of schizophrenia. Schizophr Res 13(3):195-207.
20. Huang JT, Leweke FM, Oxley D, Wang L, Harris N, Koethe D, et al. 2006. Disease biomarkers in cerebrospinal fl uid of patients with fi rst-onset psychosis. PLoS Med 3(11):e428.
21. Huang JT, Leweke FM, Tsang TM, Koethe D, Kranaster L, Gerth CW, et al. 2007. CSF metabolic and proteomic profi les in patients prodromal for psychosis. PLoS One 2(1):e756.
22. Huang JT, Wang L, Prabakaran S, Wengenroth M, Lockstone HE, Koethe D, et al. 2008. Independent protein-profi ling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues. Mol Psychiatry 13(12): 1118-1128.
23. Johnston-Wilson NL, Sims CD, Hofmann JP, Anderson L, Shore AD, Torrey EF, Yolken RH. 2000. Disease-specifi c alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropa-thology Consortium. Mol Psychiatry 5(2):142-149.
24. Jönsson E, Lannfelt L, Engvall B, Sedvall G. 1996. Lack of association between schizophrenia and the apolipoprotein E epsilon 4 allele. Eur Arch Psychiatry Clin Neurosci 246(4):182-184.
25. Kay SR, Fiszbein A, Opler LA. 1987. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276.
26. Kim DH, Iijima H, Goto K, Sakai J, Ishii H, Kim HJ, et al. 1996. Human apolipoprotein E receptor 2. A novel lipoprotein receptor of the low density lipoprotein receptor family predominantly expressed in brain. J Biol Chem 271(14):8373-8380.
27. Kirov G, Zaharieva I, Georgieva L, Moskvina V, Nikolov I, Cichon S, et al. 2009. A genome-wide association study in 574 schizophrenia trios using DNA pooling. Mol Psychiatry 14(8):796-803.
28. La YJ, Wan CL, Zhu H, Yang YF, Chen YS, Pan YX, et al. 2007. Decreased levels of apolipoprotein A-I in plasma of schizophrenic patients. J Neural Transm 114(5):657-663.
29. Lan TH, Hong CJ, Chen JY, Sim CB. 1997. Apolipoprotein E-epsilon 4 frequency in patients with schizophrenia. Biol Psychiatry 42(3):225-227.
30. Laws SM, Hone E, Gandy S, Martins RN. 2003. Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription. J Neurochem 84(6): 1215-1236.
31. Lee MK, Park AJ, Nam BY, Min KJ, Kee BS, Park DB. 2001. Apolipoprotein E genotype in Korean schizophrenic patients. J Korean Med Sci 16(6):781-783.
32. Leliveld SR, Hendriks P, Michel M, Sajnani G, Bader V, Trossbach S, et al. 2009. Oligomer assembly of the C-terminal DISC1 domain (640-854) is controlled by self-association motifs and disease-associated polymorphism S704C. Biochemistry 48(32): 7746-7755.
33. Li Q, Cheung C, Wei R, Hui ES, Feldon J, Meyer U, et al. 2009. Prenatal immune challenge is an environmental risk factor for brain and behavior change relevant to schizophrenia: evidence from MRI in a mouse model. PLoS One 4(7):e6354.
34. Liang X, Wu L, Hand T, Andreasson K. 2005. Prostaglandin D2 mediates neuronal protection via the DP1 receptor. J Neuro-chem 92(3):477-486.
35. Lieberman J, Chakos M, Wu H, Alvir J, Hoffman E, Robinson D, Bilder R. 2001. Longitudinal study of brain morphology in fi rst episode schizophrenia. Biol Psychiatry 49(6):487-499.
36. Liu W, Breen G, Zhang J, Li S, Gu N, Feng G, et al. 2003. Association of APOE gene with schizophrenia in Chinese: a poss ible risk factor in times of malnutrition. Schizophr Res 62(3):225-230.
37. Liu M, Eguchi N, Yamasaki Y, Urade Y, Hattori N, Urabe T. 2009. Protective role of hematopoietic prostaglandin D synthase in transient focal cerebral ischemia in mice. Neuroscience 163(1):296-307.
38. Mahley R.W. 1988. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240(4852):622-630.
39. Martins-de-Souza D, Gattaz WF, Schmitt A, Rewerts C, Marangoni S, Novello JC, et al. 2009a. Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis. J Neural Transm 116:275-289
40. Martins-de-Souza D, Gattaz WF, Schmitt A, Novello JC, Marangoni S, Turck CW, Dias-Neto E. 2009b. Proteome analysis of schizophrenia patients Wernicke's area reveals an energy metabolism dysregulation BMC Psychiatry 9:17
41. Martins-de-Souza D. 2010. Is the word 'biomarker' being properly used by proteomics research in neuroscience? Eur Arch Psychiatry Clin Neurosci.
42. Martins-de-Souza D, Menezes de Oliveira B, dos Santos Farias A, Horiuchi RS, Crepaldi Domingues C, de Paula E, et al. 2007. The use of ASB-14 in combination with CHAPS is the best for solubilization of human brain proteins for two-dimensional gel electrophoresis. Brief Funct Genomic Proteomic 6(1):70-75.
43. Martins-de-Souza D, Oliveira BM, Castro-Dias E, Winck FV, Horiuchi RS, Baldasso PA, et al. 2008. The untiring search for the most complete proteome representation: reviewing the methods. Brief Funct Genomic Proteomic 7(4):312-321.
44. Martins-de-Souza D, Gattaz WF, Schmitt A, Maccarrone G, Hunyadi-Guly á s E, Eberlin MN, et al. 2009c. Proteomic analysis of dorsolateral pre-frontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia. J Psychiatr Res 43(11): 978-986.
45. Mauch DH, Nägler K, Schumacher S, Göritz C, Müller EC, Otto A, Pfrieger F W. 2001. CNS synaptogenesis promoted by glia-derived cholesterol. Science 294(5545):1354-1357.
46. Mirnics K, Middleton FA, Marquez A, Lewis DA, Levitt P. 2000. Molecular characterization of schizophrenia viewed by micro-array analysis of gene expression in prefrontal cortex. Neuron 28(1):53-67.
47. Nathan BP, Jiang Y, Wong GK, Shen F, Brewer GJ, Struble RG. 2002. Apolipoprotein E4 inhibits, and apolipoprotein E3 promotes neurite outgrowth in cultured adult mouse cortical neurons through the low-density lipoprotein receptor-related protein. Brain Res 928(1-2):96-105.
48. Numata S, Ueno S, Iga J, Yamauchi K, Hongwei S, Hashimoto R, et al. 2008. TGFBR2 gene expression and genetic association with schizophrenia. J Psychiatr Res 42(6):425-432.
49. Pickar D, Malhotra AK, Rooney W, Breier A, Goldman D. 1997. Apolipoprotein E epsilon 4 and clinical phenotype in schizophrenia. Lancet 350(9082):930-931.
50. Pitas RE, Boyles JK, Lee SH, Foss D, Mahley RW. 1987. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim Biophys Acta 917(1):148-161.
51. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, Griffi n JL, et al. 2004. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxi-dative stress. Mol Psychiatry 9(7):684-697. (Pubitemid 38932173)
52. Prabakaran S, Wengenroth M, Lockstone HE, Lilley K, Leweke FM, Bahn S. 2007. 2-D DIGE analysis of liver and red blood cells provides further evidence for oxidative stress in schizophrenia. J Proteome Res 6(1):141-149.
53. Ruano D, Macedo A, João Soares M, Valente J, Helena Azevedo M, Pato C, et al. 2007. Family-based and case-control studies reveal no association of lipocalin-type prostaglandin D2 syn-thase with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 144B(5):642-646.
54. Rudin DO. 1979. Covert transport dysfunction in the choroid plexus as a possible cause of schizophrenia. Schizophr Bull 5(4):623-626.
55. Sáiz PA, Morales B, Portilla MPG, Alvarez V, Coto E, Fernández JM, et al. 2002. Apolipoprotein E genotype and schizophrenia: further negative evidence. Acta Psychiatr Scand 105(1):71-75.
56. Saleem S, Zhuang H, de Brum-Fernandes AJ, Maruyama T, Narumiya S, Dor é S. 2007. PGD(2) DP1 receptor protects brain from ischemia-reperfusion injury. Eur J Neurosci 26(1):73-78.
57. Saleem S, Shah ZA, Urade Y, Dor é S. 2009. Lipocalin-prostaglandin D synthase is a critical benefi cial factor in transient and permanent focal cerebral ischemia. Neuroscience 160(1):248-254.
58. Sandyk R. 1993. Choroid plexus calcifi cation as a possible marker of hallucinations in schizophrenia. Int J Neurosci 71(1-4): 87-92.
59. Schmitt A, Wilczek K, Blennow K, Maras A, Jatzko A, Petroianu G, et al. 2004. Altered thalamic membrane phospholipids in schizophrenia: a postmortem study. Biol Psychiatry 56(1):41-45.
60. Schürhoff F, Krebs MO, Szöke A, Loze JY, Goldberger C, Quignon V, et al. 2003. Apolipoprotein E in schizophrenia: a French association study and meta-analysis. Am J Med Genet B Neuropsychiatr Genet 119B(1):18-23.
61. Shinkai T, Ohmori O, Kojima H, Terao T, Suzuki T, Abe K, Nakamura J. 1998. Apolipoprotein E regulatory region genotype in schizophrenia. Neurosci Lett 256(1):57-60.
62. Skosnik PD, Yao JK. 2003. From membrane phospholipid defects to altered neurotransmission: is arachidonic acid a nexus in the pathophysiology of schizophrenia? Prostaglandins Leukot Essent Fatty Acids 69(6):367-384.
63. Stone JM, Morrison PD, Pilowsky LS. 2007. Glutamate and dopamine dysregulation in schizophrenia\a synthesis and selective review. J Psychopharmacol 21(4):440-552.
64. Thibaut F, Coron B, Hannequin D, Segard L, Martin C, Dollfus S, et al. 1998. No association of apolipoprotein epsilon 4 allele with schizophrenia even in cognitively impaired patients. Schiz-ophr Res 30(2):149-153.
65. Traina G, Federighi G, Brunelli M, Scuri R. 2009. Cytoprotec-tive effect of acetyl-L-carnitine evidenced by analysis of gene expression in the rat brain. Mol Neurobiol 39(2):101-106.
66. Uchihara T, Duyckaerts C, He Y, Kobayashi K, Seilhean D, Amouyel P, Hauw JJ. 1995. ApoE immunoreactivity and microglial cells in Alzheimer's disease brain. Neurosci Lett 195(1):5-8. Vawter MP, Barrett T, Cheadle C, Sokolov BP, Wood WH 3rd
67. Vawter MP, Barrett T, Cheadle C, Sokolov BP, Wood WH 3rd, Donovan DM, et al. 2001. Application of cDNA microarrays to examine gene expression differences in schizophrenia. Brain Res Bull 55(5):641-650.
68. Wittchen HU, Wunderlich U, Gruschwitz S, Zaudig M. 1997. Strukturiertes Klinisches Interview f ü r DSM-IV. Achse I: Psychische St ö rungen. A German, advanced adaptation of the original SCID version by RL Spitzer, JB Williams, M Gibbon, MB First. G ö ttingen: Hogrefe-Verlag.
69. Woods SW. 2003. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 64:663-667.
70. Wu L, Wang Q, Liang X, Andreasson K. 2007. Divergent effects of prostaglandin receptor signaling on neuronal survival. Neurosci Lett 421(3):253-258.
71. Xu MQ, St Clair D, He L. 2006. Meta-analysis of association between ApoE epsilon4 allele and schizophrenia. Schizophr Res 84(2-3):228-235.
72. Yao JK, Leonard S, Reddy RD. 2000. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr Res 42(1):7-17.
73. Yao JK, Reddy RD. 2002. Membrane pathology in schizophrenia: implication for arachidonic acid signaling. Sci. World J 2: 1922-1936.